Business Context and Reporting Period
This Form 8-K, dated September 26, 2019, reports on the reconvened Special Meeting of Stockholders for Histogenics Corporation. The filing details the approval of a merger agreement with Ocugen, Inc., which will result in Histogenics changing its corporate name to Ocugen, Inc. The meeting was previously adjourned on September 12, 2019, to solicit additional proxies.
Key Financial Metrics
This filing is a current report regarding corporate governance and merger approvals. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
On September 26, 2019, stockholders approved six proposals necessary to consummate the merger and reorganization. The total number of shares entitled to vote was 94,599,601, with 53,597,647 shares present or represented by proxy. All binding proposals were approved:
- Proposal 1 (Merger Agreement): Approved with 52,523,597 votes for, 821,937 against, and 252,113 abstentions.
- Proposal 2 (Reverse Stock Split): Approved a split of one new share for every 53 to 67 shares outstanding. Results: 49,776,420 for, 2,927,750 against, 893,477 abstentions.
- Proposal 3 (Name Change): Approved changing the name from Histogenics Corporation to Ocugen, Inc. Results: 52,077,934 for, 1,173,714 against, 345,999 abstentions.
- Proposal 4 (Authorized Shares): Approved increasing authorized common stock to 200,000,000 shares. Results: 48,120,406 for, 4,837,167 against, 640,074 abstentions.
- Proposal 5 (Warrant Issuance): Approved issuance of shares upon exercise of Investor Warrants and additional shares post-financing. Results: 50,505,516 for, 1,899,377 against, 1,192,754 abstentions.
- Proposal 6 (Adjournment): Approved adjournment if necessary to solicit additional proxies. Results: 51,040,620 for, 1,569,963 against, 987,064 abstentions.
Outlook, Risks, and Management Commentary
Management announced that all proposals related to the Merger were approved, clearing the path for the transaction to close. The filing references a definitive proxy statement/prospectus filed on Form S-4 (effective August 6, 2019) for detailed information regarding the business combination, risks, and contingencies. No specific forward-looking guidance or financial outlook is provided in this specific 8-K document.
Investor Verification Checklist
- Verify the final closing date of the merger between Histogenics and Ocugen.
- Confirm the exact reverse stock split ratio selected by the board within the approved 53-to-67 range.
- Review the Form S-4 proxy statement for details on the Pre-Merger Financing and warrant terms.
- Monitor Nasdaq filings for the official ticker symbol change and trading status of the new entity, Ocugen, Inc.
- Check for any subsequent filings regarding the issuance of shares to Ocugen stockholders as per the Merger Agreement.